[go: up one dir, main page]

WO2018007624A1 - Dérivés d'enzalutamide pour le traitement du cancer de la prostate et du sein - Google Patents

Dérivés d'enzalutamide pour le traitement du cancer de la prostate et du sein Download PDF

Info

Publication number
WO2018007624A1
WO2018007624A1 PCT/EP2017/067159 EP2017067159W WO2018007624A1 WO 2018007624 A1 WO2018007624 A1 WO 2018007624A1 EP 2017067159 W EP2017067159 W EP 2017067159W WO 2018007624 A1 WO2018007624 A1 WO 2018007624A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
acid
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2017/067159
Other languages
English (en)
Inventor
Haraldur GARDARSSON
Stefan Einar Stefansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actavis Group PTC ehf
Original Assignee
Actavis Group PTC ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1611917.4A external-priority patent/GB201611917D0/en
Priority claimed from GBGB1611916.6A external-priority patent/GB201611916D0/en
Application filed by Actavis Group PTC ehf filed Critical Actavis Group PTC ehf
Publication of WO2018007624A1 publication Critical patent/WO2018007624A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to diarylhydantoin compounds for use in the treatment of prostate cancer, in particular castration-resistant prostate cancer, and breast cancer.
  • the early disease stage is often characterised by a confined and localised tumour. Diagnosis of prostate cancer within the early disease stage allows practitioners to treat patients by invasive surgery or radiation therapy. In situations where patients are diagnosed at a more advanced stage i.e. when metastasis has occurred, the use of small molecule therapeutics becomes necessary.
  • Prostate cancer cell growth is a hormone dependent process.
  • testosterone binds to the androgen receptor (AR) which in turn leads to activation of the receptor.
  • AR activation initiates a biochemical cascade that ultimately fuels the growth of prostate cancer cells.
  • Targeting this biochemical pathway through reducing the levels of biological androgens e.g. testosterone
  • offers an effective approach to the short-term management of the disease i.e. stopping or slowing tumour growth).
  • Castration-resistant prostate cancer is diagnosed and defined by the ability of cancer cells to continue to grow under circumstances in which hormone levels have been supressed or reduced through surgical or small molecule intervention. Most typically, the disease state is characterised by metastases of the cancer to remote sites away from the prostate. In such cases prostate cancer most commonly metastasises to the bone.
  • the small molecule therapeutic bicalutamide is one example of an antiandrogen used in the treatment of prostate cancer, and is represented by the following structure:
  • Bicalutamide binds to the androgen receptor disrupting testosterone's ability to do the same.
  • the drug loses efficacy against AR when the cancer develops into a hormone refractory or hormone independent state.
  • Enzalutamide displays a higher binding affinity for AR in comparison to bicalutamide. Most importantly, unlike bicalutamide, enzalutamide also prevents the translocation of AR to the cell nucleus and in doing so prevents AR binding to DNA and other cofactors. It is this enhanced activity that led to the approval of enzalutamide as a treatment for castration-resistant prostate cancer.
  • WO 2006/1241 18 describes enzalutamide amongst a series of structurally related compounds and also provides synthetic approaches to access them.
  • WO 2010/099238 describes metabolites of enzalutamide, and in particular compounds MI-MV which are represented by the following structures:
  • Ml is a biologically inactive metabolite of enzalutamide and conversely that Mil is a biologically active metabolite of enzalutamide (see WO 2010/099238).
  • the invention provides a compound of formula (I) or ( ⁇ )
  • the invention provides a compound of formula (I)
  • the invention provides a compound of formula ( ⁇ )
  • the compound of formula (I) is a trityl-protected derivative of enzalutamide.
  • the compound of formula ( ⁇ ) is a xanthene-protected derivative of enzalutamide.
  • the trityl and xanthene derivatives provide compounds with certain improved properties compared to their methyl amide equivalent (e.g. enzalutamide).
  • the compounds of formula (I) and ( ⁇ ) may have physiochemical properties more suitable for oral exposure, for example improved oral bioavailability and/or a longer half-life, and therefore exhibit reduced dosage requirements.
  • the compounds of formula (I) and ( ⁇ ) may have fewer active metabolites and therefore are potentially less toxic.
  • the compounds of formula (I) and ( ⁇ ) have higher organic solubility than enzalutamide and therefore can have a higher drug load in liquid-filled capsules.
  • the invention provides a pharmaceutical composition comprising a compound of formula (I) or ( ⁇ ) or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
  • the invention provides a compound of formula (I) or ( ⁇ ) for use in therapy or for use in medicine.
  • the invention provides: - a compound of formula (I) or ( ⁇ ) or a salt thereof or a pharmaceutical composition comprising a compound of formula (I) or ( ⁇ ) or a pharmaceutically acceptable salt thereof for use in the treatment of prostate cancer, e.g. castration-resistant prostate cancer or hormone-refractory prostate cancer, or breast cancer;
  • prostate cancer e.g. castration-resistant prostate cancer or hormone-refractory prostate cancer, or breast cancer
  • prostate cancer e.g. castration-resistant prostate cancer or hormone-refractory prostate cancer, or breast cancer
  • administering a compound of formula (I) or ( ⁇ ) or a salt thereof or a pharmaceutical composition comprising a compound of formula (I) or ( ⁇ ) or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • the invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (II) with triphenylmethanol
  • the reaction takes place in the presence of an acid, for example a protic acid or a Lewis acid.
  • an acid for example a protic acid or a Lewis acid.
  • the invention provides a process for preparing a compound of formula ( ⁇ ) or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (II) and a compound of formula (III)
  • the reaction takes place in the presence of an acid, for example a protic acid or a Lewis acid.
  • an acid for example a protic acid or a Lewis acid.
  • references herein to the compound of formula (I) include the free base as well as ionic, salt, solvate, N-oxide, and protected forms thereof, for example, as discussed below.
  • the compound of formula (I) or ( ⁇ ) is in the form of a free base.
  • the compound of formula (I) or ( ⁇ ) includes variants with one or more isotopic substitutions, and a reference to a particular element includes within its scope all isotopes of the element.
  • a reference to hydrogen includes within its scope H, 2 H (D), and 3 H (T).
  • references to carbon and oxygen include within their scope respectively 2 C, 3 C and 4 C and 6 0 and 8 0.
  • any polymorphic forms of the compounds e.g. hydrates
  • complexes e.g. inclusion complexes or clathrates with compounds such as cyclodextrins, or complexes with metals
  • the compound of formula (I) can be prepared by a process comprising reacting a compound of formula (II) with triphenylmethanol.
  • the compound of formula (I) is reacted with triphenylmethanol in the presence of an acid e.g. a protic acid or a Lewis acid.
  • an acid e.g. a protic acid or a Lewis acid.
  • the invention provides a process for preparing a compound of formula ( ⁇ ) or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (II) and a compound of formu
  • reaction takes place in the presence of an acid, for example a protic acid or a Lewis acid.
  • an acid for example a protic acid or a Lewis acid.
  • protic acid should be understood as encompassing acids that can be described by both, or either of the Arrhenius acid and Bransted-Lowry acid definitions.
  • An Arrhenius acid is a substance that, when added to water, increases the concentration of protons (H + ) ions in the water.
  • H + protons
  • a Br0nsted-Lowry acid is a species that donates a proton to a Bransted-Lowry base (a proton acceptor). The following equations demonstrate the use and applicability of each of the Arrhenius and Br0nsted-Lowry definitions, the protic acid exemplified being acetic acid:
  • Equation (a) can be described by both definitions of protic acid.
  • acetic acid can be said to act as an Arrhenius acid, because following addition to, or reaction with water, the concentration of H 3 0 + increases.
  • acetic acid is also acting as a Br0nsted-Lowry acid by donating a proton to water.
  • Equation (b) highlights a similar situation wherein acetic acid donates a proton to ammonia and thus again behaves like a Bransted-Lowry acid, however equation (b) cannot be described by the Arrhenius definition, because the reaction is occurring in the absence of water.
  • protic acids examples include acetic acid, formic acid, sulfuric acid, hydrochloric acid, p-toluenesulfonic acid, methanesulfonic acid, trifluoromethanesulfonic acid, trifluoroacetic acid, phosphoric acid, benzoic acid, citric acid, tartaric acid, nitric acid, hydrobromic acid, hydrofluoric acid, carbonic acid, potassium bisulfate, anthranilic acid, ethylenediaminetetraacetic acid, fumaric acid, glycolic acid, lactic acid, maleic acid, malonic acid, oxalic acid, peracetic acid, propionic acid, phthalic acid, salicyclic acid, succinic acid and sulfamic acid.
  • acetic acid formic acid, sulfuric acid, hydrochloric acid, p-toluenesulfonic acid, methanesulfonic acid, trifluoromethanesulfonic acid, trifluoroace
  • protic acid is intended to cover protic acids that when added to water in an amount sufficient to form a 1 molar aqueous solution at 25°C, the resulting solution will have pH less than 7 when measured by conventional methods e.g. a pH meter.
  • Lewis acid should be understood as encompassing a species that can accept a pair of electrons (e.g. either in a covalent chemical bonding or chemical co-ordination event) from a Lewis base.
  • Lewis acids examples include AICI 3 , AIBr 3 , BF 3 .OEt 2 , Cu(OTf) 2 , Yb(OTf) 2 , Yb(OTf) 3 , SnCI 4 , TiCI 4 and Ti(0/Pr) 4 .
  • Lewis acid compounds comprising any of the metals in the following oxidation state are also suitable for use in conjunction with the present invention, Li + , Na + , K + , Be 2+ , Mg 2+ , Ca 2+ , Sr 2+ , Al 3+ , Ga 3+ , ln 3+ , Sn 2+ , Sc 3+ , La 3+ , Ti 4+ , Zr 4+ , Cr 3+ , Fe 3+ , Co 3+ , lr 3+ , Th 4+ and Yb 3+ .
  • the process for preparing a compound of formula (I) or ( ⁇ ) is preferably conducted in a solvent (i.e. an organic solvent) or a mixture of solvents.
  • water- or air-sensitive transformations require the use of non-aqueous, non-protic solvents such as acetonitrile, tetrahydrofuran, dioxane, dimethylsulfoxide dichloromethane, chloroform or A/-methylpyrrolidine.
  • non-aqueous, non-protic solvents such as acetonitrile, tetrahydrofuran, dioxane, dimethylsulfoxide dichloromethane, chloroform or A/-methylpyrrolidine.
  • water- or air- sensitive reactions may also require an atmosphere of inert gas (to prevent atmospheric water from compromising a transformation) typical inert gases include nitrogen and argon.
  • an aqueous reagent e.g.
  • aqueous hydrochloric acid or aqueous sodium hydroxide may require the use of one or more organic co-solvents.
  • an organic co- solvent is added to aid the dissolution, or partial dissolution of a less polar organic reagent.
  • Typical organic co-solvents for use with such aqueous reagents include, toluene, alcohols (methanol, ethanol, propanol), tetrahydrofuran and dimethylsulfoxide.
  • reaction efficacy when using organic co-solvents with aqueous solvents is the requirement for some degree of miscibility of the organic co-solvent with water.
  • phase transfer catalyst e.g. tetrabutylammonium bromide.
  • Solvents are traditionally categorised into two categories, polar and non-polar. More specifically solvents are allocated into each category according to their dielectric constant. It is generally accepted that solvents displaying a dielectric constant of less than 15 are considered to be non-polar solvents, and solvents displaying a dielectric constant of greater than or equal to 15 are considered to be polar solvents.
  • Preferred solvents for use in preparing a compound of formula (I) or ( ⁇ ) are non-polar solvents.
  • a particularly preferred solvent for use in preparing a compound of formula (I) or ( ⁇ ) is benzene or toluene.
  • Recrystallisation of a final compound removes the need for conventional column chromatography and high-performance liquid chromatography techniques, which although well-established and ubiquitous in discovery chemistry, present an unwanted economic and time burden to chemists operating at the process level (i.e. producing multi-kilogram and multi-tonne quantities of drug). Recrystallisation of the final compound also provides an opportunity of reducing upstream purifications through telescoping of individual reaction steps (wherein two or more, previously independent synthetic transformations converge into a "single" process and therefore require only one purification step).
  • a process of preparing a compound of formula ( ⁇ ), comprising reacting a compound of formula (II) with a compound of formula (III), in the presence of a protic acid or a Lewis acid is conducted in benzene or toluene and wherein the compound of formula ( ⁇ ) is recrystallised from an alcoholic solvent.
  • the product of the process can be a compound of formula (I) or ( ⁇ ) or a pharmaceutically acceptable salt or solvate thereof.
  • the compound of formula (I) is provided in a 5-step linear sequence starting from commercially available 2-fluoro-4-nitrobenzoic acid.
  • the synthesis begins with a functional group interconversion of a benzoic acid moiety into a benzamide via an acyl chloride mediated amidation reaction.
  • the p-nitro group is reduced to the corresponding amine via hydrogen transfer over iron metal and acetic acid.
  • the resulting aniline derivative then undergoes a Sn1 alkylation reaction with ethyl bromoisobutyrate and in so forms a coupling partner for the subsequent condensation reaction with 3-trifluromethyl-4-cyanophenyl isothiocyanate.
  • the condensation reaction provides N-desmethyl enzalutamide, which then undergoes a further Sn1 alkylation reaction with trityl alcohol in the presence of paratoluenesulfonic acid (PTSA) to generate the desired trityl derivative.
  • PTSA paratoluenesulfonic acid
  • the compound of formula (III) is available in a single step via the reduction of xanthone with a hydride reagent, for example sodium borohydride, according to the following synthetic approach:
  • the compound of formula ( ⁇ ) is provided in a 5-step linear sequence starting from commercially available 2-fluoro-4-nitrobenzoic acid.
  • the synthesis begins with a functional group interconversion of a benzoic acid moiety into a benzamide via an acyl chloride mediated amidation reaction. Following installation of the amide, the p-nitro group is reduced to the corresponding amine via hydrogen transfer over iron metal and acetic acid.
  • the resulting aniline derivative then undergoes a Sn1 alkylation reaction with ethyl bromoisobutyrate and so forms a coupling partner for the subsequent condensation reaction with 3-trifluromethyl-4-cyanophenyl isothiocyanate.
  • the condensation reaction provides N-desmethyl enzalutamide, which then undergoes a further Sn1 alkylation reaction with xanthydrol (III) in the presence of acetic acid to generate the desired xanthene derivative.
  • the ieri-butyl carbonate-containing derivative might also provide a derivative with one or more improved pharmacokinetic properties (e.g. compared to enzalutamide).
  • the compound of formula (IV) was accessed according to the following synthetic approach:
  • the ieri-butyl carbonate-containing derivative was available from the reaction of N-desmethyl enzalutamide with di-ieri-butyl dicarbonate in the presence of 4-(dimethylamino) pyridine.
  • composition e.g. formulation
  • a pharmaceutical composition comprising a compound of formula (I) or ( ⁇ ) together with one or more pharmaceutically acceptable excipients, carriers, adjuvants, diluents, fillers, buffers, stabilisers, preservatives, lubricants, or other materials well known to those skilled in the art and optionally other therapeutic or prophylactic agents.
  • pharmaceutically acceptable refers to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of a subject (e.g. human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • a subject e.g. human
  • Each excipient, carrier, etc. must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.
  • compositions can be in any form suitable for oral, parenteral, topical, intranasal, ophthalmic, otic, rectal, intra-vaginal, or transdermal administration.
  • compositions are intended for parenteral administration, they can be formulated for intravenous, intramuscular, intraperitoneal, subcutaneous administration or for direct delivery into a target organ or tissue by injection, infusion or other means of delivery.
  • Pharmaceutical dosage forms suitable for oral administration include tablets, capsules, caplets, pills, lozenges, syrups, solutions, powders, granules, elixirs and suspensions, sublingual tablets, wafers or patches and buccal patches.
  • a preferred composition is one in which the formulation is provided in a capsule.
  • Capsule formulations may be of the hard gelatin or soft gelatin variety and can contain the active component in solid, semi-solid, or liquid form.
  • Gelatin capsules can be formed from animal gelatin or synthetic or plant derived equivalents thereof.
  • a particularly preferred capsule formulation comprises a compound of formula (I) or ( ⁇ ), and one or more excipient selected from caprylocaproyl macrogol-8 glycerides, butylhydroxyanisole and butylhydroxytoluene.
  • the compound the compound of formula (I) or ( ⁇ ) has higher organic solubility than enzalutamide and therefore can have a higher drug load in the preferred liquid-filled capsules.
  • compositions containing a compound of formula (I) or ( ⁇ ) can be formulated in accordance with known techniques, see for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA.
  • the compound of formula (I) or ( ⁇ ) will generally be presented in unit dosage form and, as such, will typically contain sufficient compound to provide a desired level of biological activity.
  • a formulation intended for oral administration may contain from 1 ng to 2 mg, for example 0.1 mg to 2 g of active ingredient, more usually from 10 mg to 1 g, e.g. 50 mg to 500 mg, or 0.1 mg to 2 mg.
  • the capsules comprise a compound of formula (I) or ( ⁇ ) in an amount of 1 to 250 mg, it is more preferred wherein the capsules comprise a compound of formula (I) or ( ⁇ ) in an amount of 50 to 250 mg.
  • the compound of formula (I) or ( ⁇ ) will be administered to a patient in need thereof (for example a human or animal patient) in an amount sufficient to achieve the desired therapeutic effect.
  • Therapeutic uses provides a compound of formula (I) or ( ⁇ ) for use in therapy.
  • Metabolite MM is active against the androgen receptor (AR) and thus by extension, the compounds of formula (I) and ( ⁇ ) are therefore also suited towards diseases that are dependent upon and modulated by the activity of the androgen receptor.
  • the present invention provides a compound of formula (I) or ( ⁇ ) for use in the treatment of prostate cancer, and in particular castration-resistant prostate cancer or hormone-refractory prostate cancer.
  • the compound will typically be administered in an amount that is therapeutically or prophylactically useful and which is generally non-toxic.
  • the compound may be administered over a prolonged term to maintain beneficial therapeutic effects or may be administered for a short period only. Alternatively, the compound may be administered in a pulsatile manner.
  • a typical daily dose of the compound can be in the range from 100 pg to 100 mg per kilogram of body weight, typically 10 ng to 10 mg per kilogram of bodyweight, more typically 1 ⁇ g to 10 mg although higher or lower doses may be administered where required.
  • the quantity of compound administered will be commensurate with the nature of the disease or physiological condition being treated and will be at the discretion of the physician.
  • the compound of the formula (I) or ( ⁇ ) can be administered as the sole therapeutic agent or can be administered in combination therapy with one of more other compounds for treatment of a particular disease state.
  • the compounds can be administered simultaneously or sequentially. When administered sequentially, they can be administered at closely spaced intervals (for example over a period of 5-10 minutes) or at longer intervals (for example 1 , 2, 3, 4 or more hours apart, or even longer periods apart where required), the precise dosage regimen being commensurate with the properties of the therapeutic agent(s).
  • the compound of formula (I) or ( ⁇ ) may also be administered in conjunction with non- chemotherapeutic treatments such as radiotherapy, photodynamic therapy, gene therapy; surgery and controlled diets.
  • non- chemotherapeutic treatments such as radiotherapy, photodynamic therapy, gene therapy; surgery and controlled diets.
  • the compound of formula (I) or ( ⁇ ) and one, two, three, four or more other therapeutic agents can be, for example, formulated together in a dosage form containing two, three, four or more therapeutic agents.
  • the individual therapeutic agents may be formulated separately and presented together in the form of a kit, optionally with instructions for their use.
  • a person skilled in the art would know through their common general knowledge the dosing regimens and combination therapies to use. The present invention will now be described with reference to the examples, which are not intended to be limiting.
  • Trityl alcohol (8.6 g), N-desmethyl enzalutamide (10 g) and PTSA (2.5 g) were added to benzene (100 mL) at a temperature of 20-30°C.
  • the reaction mixture was heated to 80-85°C and allowed to stir for 3-4 hours. Following which, the reaction mixture was allowed to cool to 10-15°C and stirred for a further 30-60 minutes.
  • the solid precipitate was filtered and the filter cake washed with benzene (15 mL).
  • the product was collected and recrystallised from isopropyl alcohol (450 mL) to obtain the desired product (15 g).
  • the product could be further purified by performing a second recrystallisation from methanol, to obtain the desired product (10 g).
  • benzamide was added to trifluoroacetic acid (9 mL), dichloromethane (0.5 mL) and water (0.5 mL) at a temperature of 20-30°C and stirred for 2 hours. The mixture was allowed to cool to a temperature of 10-20°C and the pH was adjusted to 7-7.5 using a 5% NaOH solution. The mixture was diluted with H 2 0 (10 mL) and extracted with ethyl acetate (2 x 10 mL). The combined organic layers were concentrated under reduced pressure (at a temperature below 50°C) to obtain a residue. The residue was then analysed by HPLC to identify the proportion of deprotected product. Analysis indicated less than 1 % of unreacted starting material and greater than 90% conversion to N-desmethyl enzalutamide.
  • Xanthyldrol (1 1 g) and N-desmethyl enzalutamide (10 g) were added to acetic acid at a temperature of 20-30°C.
  • the reaction mixture was heated to 80-85°C and allowed to stir for 3-4 hours.
  • the reaction mixture was then allowed to cool to 20-30°C.
  • Dichloromethane (100 mL) and demineralised water (100 mL) were then added to the mixture and the mixture was heated with stirring at 40-45°C for 30 minutes.
  • the layers were then separated and the aqueous layer was extracted with dichloromethane (2 x 50 mL).
  • the combined organic layers were concentrated under reduced pressure (at a temperature below 50°C) to obtain the crude product.
  • N-desmethyl enzalutamide (1 g) and DMAP (0.1 g) were added to dichloromethane (20 mL) at a temperature of 20-30°C.
  • di-ieri-butyl dicarbonate (1 .1 mL) was added to the reaction mixture and the mixture was stirred at 20-30°C for 3-4 hours.
  • the reaction mixture was then concentrated under reduced pressure (at a temperature below 30°C) to obtain a residue.
  • the residue was purified using neutral alumina column chromatography (n-hexanes:ethyl acetate) to obtain the desired product as a viscous oil.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un composé de formule (I) ou (I') ou un sel pharmaceutiquement accepté de celui-ci. L'invention concerne également des compositions pharmaceutiques contenant les composés, des procédés de préparation des composés et les utilisations médicales des composés.
PCT/EP2017/067159 2016-07-08 2017-07-07 Dérivés d'enzalutamide pour le traitement du cancer de la prostate et du sein Ceased WO2018007624A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1611917.4A GB201611917D0 (en) 2016-07-08 2016-07-08 Pharmaceutical agents
GB1611916.6 2016-07-08
GBGB1611916.6A GB201611916D0 (en) 2016-07-08 2016-07-08 Pharmaceutical agents
GB1611917.4 2016-07-08

Publications (1)

Publication Number Publication Date
WO2018007624A1 true WO2018007624A1 (fr) 2018-01-11

Family

ID=59298460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/067159 Ceased WO2018007624A1 (fr) 2016-07-08 2017-07-07 Dérivés d'enzalutamide pour le traitement du cancer de la prostate et du sein

Country Status (1)

Country Link
WO (1) WO2018007624A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010099238A1 (fr) * 2009-02-24 2010-09-02 Medivation Prostate Therapeutics, Inc. Composés spécifiques de type diarylhydantoïne et diarylthiohydantoïne
WO2010118354A1 (fr) * 2009-04-09 2010-10-14 Medivation Prostate Therapeutics, Inc. Composés consistant en di-arylhydantoïnes et di-arylthiohydantoïnes substituées et leurs procédés d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010099238A1 (fr) * 2009-02-24 2010-09-02 Medivation Prostate Therapeutics, Inc. Composés spécifiques de type diarylhydantoïne et diarylthiohydantoïne
WO2010118354A1 (fr) * 2009-04-09 2010-10-14 Medivation Prostate Therapeutics, Inc. Composés consistant en di-arylhydantoïnes et di-arylthiohydantoïnes substituées et leurs procédés d'utilisation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof

Similar Documents

Publication Publication Date Title
WO2021190467A1 (fr) Composé de quinazoline contenant un cycle spiro
EP3848367A1 (fr) Composés tricycliques agissant sur des protéines crbn
TW201408661A (zh) 抗病毒性化合物之固體形式
EP3866931B1 (fr) Composés contenant du deutérium
CA3021008A1 (fr) Derives de bisphenol et leur utilisation en tant que modulateurs de l'activite du recepteur des androgenes
KR100225927B1 (ko) 콜린에스테라제 저해제로서의 제네세린 유도체
CN118878557A (zh) 一种pan-KRAS抑制剂化合物
AU2017202849B2 (en) Potent and Selective Inhibitors of Monoamine Transporters; Method of Making; and Use Thereof
KR20040088474A (ko) 중수소화된 디하이드로푸라논 및 이를 함유한 약물
EP3650448A1 (fr) Dérivé d'indole-formamide, son procédé de préparation et son utilisation en médecine
EP3730509B1 (fr) Composé pour le traitement de maladies métaboliques, son procédé de préparation et son utilisation
WO2018007624A1 (fr) Dérivés d'enzalutamide pour le traitement du cancer de la prostate et du sein
CZ299292A3 (en) Benzazepine compounds for treating neurological disorders
CN108558760B (zh) 一类芳香酰胺化合物及其制备方法和用途
EP2851363B1 (fr) Composite à base de radical acide d'agomélatine et procédé de préparation et application associés
CN115974855B (zh) Ezh2和hdac双靶点抑制剂、其药物组合物及其制备方法和用途
KR20210134306A (ko) 아크릴-함유 핵 수출 조절제들 및 이들의 용도들
CN111166745A (zh) 含消旋氧吡格雷或其盐的组合物及应用
JP2001511798A (ja) オキシド−スクアレンシクラーゼ抑制剤として有用な複素環化合物
KR20210090615A (ko) N-방향족 아미드류 화합물 및 이의 제조 방법과 용도
CN117624161A (zh) 一种吡啶羧酸胺衍生物及其应用
EP4424676A1 (fr) Composé contenant du pyridyle
JPH0372468A (ja) トリアゾール化合物及びこれを含有する抗真菌剤
WO1993016052A1 (fr) Nouveau derive d'azole, sa production et composition pharmaceutique
CN112480100B (zh) 吡咯烷酮衍生物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17737268

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17737268

Country of ref document: EP

Kind code of ref document: A1